Yikai Luo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yikai Luo has a total of 208 co-authors. Here are the top co-authors by number of shared publications:
- Han Liang
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
22 shared publications - Lie Wang
Bone Marrow Transplantation Center and Institute of Immunology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
16 shared publications - Can Hu
Department of Gastric Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China
14 shared publications - Guofeng Chen
Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
14 shared publications - Jia Qi
The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
14 shared publications - Jian Chen
Department of Gastrointestinal Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
14 shared publications
Latest Publications
- 12 August 2026
- Published by Springer Nature in Nature
- Vol. 658  (8135) , 496-507
In vivo genome-wide CRISPR screens of human T cells in solid tumours
- 12 August 2026
- Published by Springer Nature in Nature
- Vol. 658  (8135) , 496-507
In vivo genome-wide CRISPR screens of human T cells in solid tumours
- Top Cited Papers
- 27 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18  (851) , eady2719
Genomic instability drives POSTN + myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer
Cancer-associated fibroblasts (CAFs) are central architects of immunosuppression and therapy resistance across malignancies, yet how tumor-intrinsic genomic instability instructs stromal reprogramming remains unresolved. Integrated single-cell transcriptomics and epigenomics of samples from patients with high-grade serous ovarian carcinoma revealed POSTN + myofibroblast-like cancer-associated fibroblasts (myCAFs) and effector regulatory T cells (eT reg cells) as critical mediators of immunosuppression in tumors with high genomic instability. Mechanistically, unstable genomes activated tumor-intrinsic STING signaling, triggering WNT3a/7a secretion. WNT/β-catenin signaling in fibroblasts established a POSTN-dependent positive feedback loop that epigenetically locked cells into a POSTN + myCAF lineage. These myCAFs reciprocally expanded eT reg cells and exhausted CD8 + T cells, thereby converting genomic instability–driven immune activation into suppression and limiting poly(ADP-ribose) polymerase inhibitor (PARPi) efficacy. Therapeutic POSTN blockade reinvigorated T cell cytotoxicity, depleted eT reg cells, and potentiated PARP inhibition in ovarian and breast cancer models, overcoming resistance. Our work resolves the dual roles of genomic instability and identifies POSTN as a stromal-specific checkpoint to mediate immunosuppression in genomically unstable tumors.
- 27 May 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18  (851) , eady2719
Top Cited PapersGenomic instability drives POSTN + myofibroblasts via STING-WNT axis to promote immunosuppression and PARPi resistance in ovarian cancer
Cancer-associated fibroblasts (CAFs) are central architects of immunosuppression and therapy resistance across malignancies, yet how tumor-intrinsic genomic instability instructs stromal reprogramming remains unresolved. Integrated single-cell transcriptomics and epigenomics of samples from patients with high-grade serous ovarian carcinoma revealed POSTN + myofibroblast-like cancer-associated fibroblasts (myCAFs) and effector regulatory T cells (eT reg cells) as critical mediators of immunosuppression in tumors with high genomic instability. Mechanistically, unstable genomes activated tumor-intrinsic STING signaling, triggering WNT3a/7a secretion. WNT/β-catenin signaling in fibroblasts established a POSTN-dependent positive feedback loop that epigenetically locked cells into a POSTN + myCAF lineage. These myCAFs reciprocally expanded eT reg cells and exhausted CD8 + T cells, thereby converting genomic instability–driven immune activation into suppression and limiting poly(ADP-ribose) polymerase inhibitor (PARPi) efficacy. Therapeutic POSTN blockade reinvigorated T cell cytotoxicity, depleted eT reg cells, and potentiated PARP inhibition in ovarian and breast cancer models, overcoming resistance. Our work resolves the dual roles of genomic instability and identifies POSTN as a stromal-specific checkpoint to mediate immunosuppression in genomically unstable tumors.
- Open Access
- 9 February 2026
- Published by Elsevier in SSRN Electronic Journal
Neoadjuvant Niraparib Monotherapy for Newly Diagnosed Unresectable HRD-Positive High-Grade Serous Ovarian Cancer (NANT): A Multicenter, Prospective, Phase 2 Trial
Background Neoadjuvant chemotherapy followed by interval debulking surgery (IDS) is standard for advanced ovarian cancer unlikely to achieve optimal cytoreduction, yet non-cytotoxic neoadjuvant options remain limited. We evaluated whether a chemotherapy-sparing neoadjuvant PARP inhibitor strategy can enable high-quality cytoreduction (R0 resection) while preserving downstream treatment deliverability, including maintenance therapy. Methods In this multicenter, prospective, single-arm, phase 2 trial (NANT), treatment-naïve patients with unresectable FIGO stage III–IV HRD-positive high-grade serous ovarian cancer were selected for a neoadjuvant approach using prespecified resectability criteria and multidisciplinary assessment. They received oral niraparib for two 28-day cycles with an individualized starting dose. Co-primary endpoints were investigator-assessed objective response rate (ORR) and R0 resection rate at IDS. Findings Between Jan 8, 2021, and Jul 18, 2023, 127 widely disseminated, unresectable patients were screened and 67 were enrolled. Among 48 response-evaluable patients, ORR was 62·5%, and the disease control rate was 87·5%. Activity was most pronounced in BRCA1/2-mutated tumors, with an ORR of 77·3% and 100% DCR. Of 40 patients undergoing IDS, 80·0% achieved R0 resection. Complex procedures were common, including bowel resection in 47·5% and upper abdominal procedures in 50·0%, with no perioperative mortality. 81·6% (31/38) achieved CR or PR after postoperative standard chemotherapy and a median maintenance therapy time was 13·6 months. At data cutoff on Dec 29, 2025, with a median 37·7 months follow-up, median progression-free survival was 19·7 months, and median overall survival was 53·2 months. Toxicities were manageable with dose modification and no treatment-related death occurred.Interpretation: Chemotherapy-free neoadjuvant niraparib showed meaningful activity and enabled high rates of complete cytoreduction, while preserving access to postoperative therapies. These findings support this strategy as a potential chemotherapy-sparing alternative for HRD-positive disease, particularly for patients with BRCA1/2 mutations.
- 9 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessNeoadjuvant Niraparib Monotherapy for Newly Diagnosed Unresectable HRD-Positive High-Grade Serous Ovarian Cancer (NANT): A Multicenter, Prospective, Phase 2 Trial
Background Neoadjuvant chemotherapy followed by interval debulking surgery (IDS) is standard for advanced ovarian cancer unlikely to achieve optimal cytoreduction, yet non-cytotoxic neoadjuvant options remain limited. We evaluated whether a chemotherapy-sparing neoadjuvant PARP inhibitor strategy can enable high-quality cytoreduction (R0 resection) while preserving downstream treatment deliverability, including maintenance therapy. Methods In this multicenter, prospective, single-arm, phase 2 trial (NANT), treatment-naïve patients with unresectable FIGO stage III–IV HRD-positive high-grade serous ovarian cancer were selected for a neoadjuvant approach using prespecified resectability criteria and multidisciplinary assessment. They received oral niraparib for two 28-day cycles with an individualized starting dose. Co-primary endpoints were investigator-assessed objective response rate (ORR) and R0 resection rate at IDS. Findings Between Jan 8, 2021, and Jul 18, 2023, 127 widely disseminated, unresectable patients were screened and 67 were enrolled. Among 48 response-evaluable patients, ORR was 62·5%, and the disease control rate was 87·5%. Activity was most pronounced in BRCA1/2-mutated tumors, with an ORR of 77·3% and 100% DCR. Of 40 patients undergoing IDS, 80·0% achieved R0 resection. Complex procedures were common, including bowel resection in 47·5% and upper abdominal procedures in 50·0%, with no perioperative mortality. 81·6% (31/38) achieved CR or PR after postoperative standard chemotherapy and a median maintenance therapy time was 13·6 months. At data cutoff on Dec 29, 2025, with a median 37·7 months follow-up, median progression-free survival was 19·7 months, and median overall survival was 53·2 months. Toxicities were manageable with dose modification and no treatment-related death occurred.Interpretation: Chemotherapy-free neoadjuvant niraparib showed meaningful activity and enabled high rates of complete cytoreduction, while preserving access to postoperative therapies. These findings support this strategy as a potential chemotherapy-sparing alternative for HRD-positive disease, particularly for patients with BRCA1/2 mutations.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S2 shows characteristics summary of patients in the GC external validation cohort
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S2 shows characteristics summary of patients in the GC external validation cohort
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S1 shows clinicopathological correlations of m-TLSs in the GC H&E cohort
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S1 shows clinicopathological correlations of m-TLSs in the GC H&E cohort
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S5 shows characteristics of colorectal cancer patients in the flow cytometry cohort
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S5 shows characteristics of colorectal cancer patients in the flow cytometry cohort
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S4 shows characteristics summary of GC patients in the flow cytometry cohort
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Table S4 shows characteristics summary of GC patients in the flow cytometry cohort
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Figure S1 shows model performance and clinical stratification metrics
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Figure S1 shows model performance and clinical stratification metrics
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Figure S2 shows spatial and maturation subtypes of TLSs and their clinical associations
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Figure S2 shows spatial and maturation subtypes of TLSs and their clinical associations
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Figure S4 shows interaction between CD8+ TRM and activated B cells in m-TLSs
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Artificial Intelligence and Multimodality Data Integration Decipher Tertiary Lymphoid Structure Maturity in Gastric Cancer
Figure S4 shows interaction between CD8+ TRM and activated B cells in m-TLSs